Novartis RNA Therapy Del-Brax Shows Success in Muscular Dystrophy Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 12 2026
0mins
Source: seekingalpha
- Clinical Trial Success: Novartis's RNA therapy del-brax has succeeded in a Phase 1/2 trial for facioscapulohumeral muscular dystrophy, marking a significant breakthrough for the company in the rare neuromuscular disease space.
- Biomarker Improvement: The trial results indicate that del-brax met primary and key secondary endpoints by showing reductions in biomarkers such as KHDC1L and creatine kinase, demonstrating its effectiveness in reducing muscle damage.
- Potential Market Leader: Novartis suggests that del-brax could become the first disease-modifying treatment for FSHD, further solidifying its leadership position in the muscular dystrophy treatment market and likely attracting increased investor interest.
- Follow-Up Trial Plans: Currently, Novartis is enrolling patients for the Phase 3 trial of del-brax and plans to share the latest results with regulators, showcasing the company's commitment to advancing innovative drug development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVS
Wall Street analysts forecast NVS stock price to fall
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 154.140
Low
112.00
Averages
127.75
High
143.00
Current: 154.140
Low
112.00
Averages
127.75
High
143.00
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novartis Receives Approval for Itvisma Gene Therapy
- Gene Therapy Approval: Novartis's Itvisma gene therapy has received approval from the European Commission, specifically designed for treating patients with 5q spinal muscular atrophy, marking a significant advancement in the rare disease sector and expected to enhance the company's competitive position in this market.
- Successful Clinical Trials: Itvisma demonstrated impressive results in the STEER clinical program, with both the Phase 1/2 STRONG trial and Phase 3b STRENGTH trial showing significant efficacy, as treated subjects exhibited an average improvement of 2.39 points on the Hammerstein Functional Motor Scale, indicating the therapy's effectiveness and sustainability.
- Market Exclusivity: Itvisma is now the only approved gene therapy for adults with SMA in the European Union, further solidifying Novartis's leadership in the gene therapy space while providing a new revenue stream for the company.
- Competitive Product Scrutiny: Novartis's other drug, Zolgensma, is under review due to liver-related side effects in infants, which clarifies Itvisma's market outlook and may attract more patients to choose this therapy.
See More
Novartis Secures EU Approval for Itvisma to Treat Spinal Muscular Atrophy
- New Treatment Option: Novartis's Itvisma (onasemnogene abeparvovec) has received EU approval, becoming the first gene replacement therapy for the broad population of 5q spinal muscular atrophy, marking a significant breakthrough in treatment options.
- Clinical Research Support: The approval is based on data from the registrational STEER study and supportive Phase IIIb STRENGTH and Phase I/II STRONG studies, demonstrating Itvisma's efficacy and safety in improving patient health outcomes.
- Market Potential: With the launch of Itvisma, Novartis is poised to capture a leading position in the European market, addressing the urgent need for spinal muscular atrophy treatments, thereby driving future revenue growth for the company.
- Market Reaction: Although Novartis shares closed at 125.00 Swiss francs, down 1.25%, the approval of the new therapy is expected to have a positive long-term impact on the company's stock price.
See More
Comparative Analysis of International Stock ETFs
- Market Coverage Differences: The iShares Core MSCI EAFE ETF (IEFA) focuses solely on developed market stocks outside the U.S. and Canada, tracking around 2,600 stocks, while the Vanguard Total International Stock ETF (VXUS) encompasses both developed and emerging markets with approximately 8,700 stocks, showcasing VXUS's broader global coverage.
- Sector Allocation Comparison: IEFA's top sector allocations are financials (23%), industrials (19%), and technology (12%), whereas VXUS has higher allocations in financials (22%), technology (21%), and industrials (15%), particularly highlighting the significant influence of technology in emerging markets, reflecting VXUS's investment potential in AI and other emerging sectors.
- Portfolio Selection: IEFA is suitable for investors looking to focus on developed markets, while VXUS offers a superior choice for those seeking comprehensive international stock coverage, especially in the context of today's diversified global economy, making VXUS's diversified strategy more appealing.
- Expense Ratio Advantage: Both ETFs boast expense ratios below 0.1%, providing competitive cost-effectiveness; however, VXUS's diversified portfolio may offer higher long-term return potential, particularly given the growth expectations in emerging markets.
See More
Comparison of Core International Stock ETFs
- ETF Fee Comparison: Both the iShares Core MSCI EAFE ETF and the Vanguard Total International Stock ETF feature expense ratios below 0.1%, enabling investors to effectively manage costs when selecting core international equity funds, thereby enhancing long-term investment returns.
- Market Coverage Differences: The iShares Core MSCI EAFE ETF focuses solely on developed markets, holding approximately 2,600 stocks with Japan and the UK accounting for nearly 40%, while the Vanguard Total International Stock ETF encompasses both developed and emerging markets with around 8,700 stocks, offering broader global investment opportunities.
- Sector Allocation Analysis: The iShares Core MSCI EAFE ETF's top sectors include financials (23%), industrials (19%), and technology (12%), whereas the Vanguard Total International Stock ETF has a higher allocation in technology (21%) alongside financials (22%) and industrials (15%), reflecting a greater emphasis on emerging fields like AI.
- Investment Choice Recommendations: For investors seeking comprehensive international stock coverage in a single fund, the Vanguard Total International Stock ETF is the superior choice, while the iShares Core MSCI EAFE ETF is suitable for those focusing exclusively on developed markets, highlighting the applicability of different investment strategies.
See More
Novartis Gene Therapy Itvisma Approved by European Commission
- Gene Therapy Approval: Novartis' gene therapy Itvisma has been approved by the European Commission for children aged two and older with spinal muscular atrophy (SMA), marking its availability across all 27 EU member states as well as Norway, Iceland, and Liechtenstein.
- Innovative Treatment Option: Itvisma is the first approved gene replacement therapy targeting a broad group of SMA patients, designed to replace the survival motor neuron 1 (SMN1) gene, thereby enhancing Novartis' product offerings in the SMA treatment landscape.
- Market Competitive Edge: Together with the existing Zolgensma therapy, Itvisma provides gene replacement therapy options for SMA patients at various stages, from newborns to adults, significantly strengthening Novartis' competitive position in the European market.
- Clinical Research Backing: The approval follows the pivotal STEER study results, which demonstrated Itvisma's statistically significant improvement on SMA disease progression scales, further solidifying Novartis' leadership in muscle disease therapies.
See More
ADMA Biologics Shows Promising Profitability Outlook
- Profitability Growth: ADMA Biologics reported a net income of $407 million in Q1, reflecting a 22% year-over-year increase, indicating sustained profitability that is expected to enhance the company's competitive edge in the biopharmaceutical market.
- Significant Market Potential: Currently capturing only 4% of its total addressable market, ADMA is positioned for substantial growth, with the market projected to expand at a compound annual growth rate of 10% through 2033, suggesting significant revenue growth opportunities ahead.
- Optimistic Product Outlook: EyePoint Pharmaceuticals is on track to announce results from clinical trials for Duravyu, targeting wet age-related macular degeneration, with a market opportunity exceeding $15 billion, which could significantly elevate the company's market position if approved.
- Investment Risks and Rewards: Viking Therapeutics has an average price target 146% above its current share price, and while it remains unprofitable, its potential in obesity drug development makes it a focal point for investors, despite the inherent investment risks.
See More
Novartis Receives Approval for Itvisma Gene Therapy
- Gene Therapy Approval: Novartis's Itvisma gene therapy has received approval from the European Commission, specifically designed for treating patients with 5q spinal muscular atrophy, marking a significant advancement in the rare disease sector and expected to enhance the company's competitive position in this market.
- Successful Clinical Trials: Itvisma demonstrated impressive results in the STEER clinical program, with both the Phase 1/2 STRONG trial and Phase 3b STRENGTH trial showing significant efficacy, as treated subjects exhibited an average improvement of 2.39 points on the Hammerstein Functional Motor Scale, indicating the therapy's effectiveness and sustainability.
- Market Exclusivity: Itvisma is now the only approved gene therapy for adults with SMA in the European Union, further solidifying Novartis's leadership in the gene therapy space while providing a new revenue stream for the company.
- Competitive Product Scrutiny: Novartis's other drug, Zolgensma, is under review due to liver-related side effects in infants, which clarifies Itvisma's market outlook and may attract more patients to choose this therapy.
See More
Novartis Secures EU Approval for Itvisma to Treat Spinal Muscular Atrophy
- New Treatment Option: Novartis's Itvisma (onasemnogene abeparvovec) has received EU approval, becoming the first gene replacement therapy for the broad population of 5q spinal muscular atrophy, marking a significant breakthrough in treatment options.
- Clinical Research Support: The approval is based on data from the registrational STEER study and supportive Phase IIIb STRENGTH and Phase I/II STRONG studies, demonstrating Itvisma's efficacy and safety in improving patient health outcomes.
- Market Potential: With the launch of Itvisma, Novartis is poised to capture a leading position in the European market, addressing the urgent need for spinal muscular atrophy treatments, thereby driving future revenue growth for the company.
- Market Reaction: Although Novartis shares closed at 125.00 Swiss francs, down 1.25%, the approval of the new therapy is expected to have a positive long-term impact on the company's stock price.
See More
Comparative Analysis of International Stock ETFs
- Market Coverage Differences: The iShares Core MSCI EAFE ETF (IEFA) focuses solely on developed market stocks outside the U.S. and Canada, tracking around 2,600 stocks, while the Vanguard Total International Stock ETF (VXUS) encompasses both developed and emerging markets with approximately 8,700 stocks, showcasing VXUS's broader global coverage.
- Sector Allocation Comparison: IEFA's top sector allocations are financials (23%), industrials (19%), and technology (12%), whereas VXUS has higher allocations in financials (22%), technology (21%), and industrials (15%), particularly highlighting the significant influence of technology in emerging markets, reflecting VXUS's investment potential in AI and other emerging sectors.
- Portfolio Selection: IEFA is suitable for investors looking to focus on developed markets, while VXUS offers a superior choice for those seeking comprehensive international stock coverage, especially in the context of today's diversified global economy, making VXUS's diversified strategy more appealing.
- Expense Ratio Advantage: Both ETFs boast expense ratios below 0.1%, providing competitive cost-effectiveness; however, VXUS's diversified portfolio may offer higher long-term return potential, particularly given the growth expectations in emerging markets.
See More
Comparison of Core International Stock ETFs
- ETF Fee Comparison: Both the iShares Core MSCI EAFE ETF and the Vanguard Total International Stock ETF feature expense ratios below 0.1%, enabling investors to effectively manage costs when selecting core international equity funds, thereby enhancing long-term investment returns.
- Market Coverage Differences: The iShares Core MSCI EAFE ETF focuses solely on developed markets, holding approximately 2,600 stocks with Japan and the UK accounting for nearly 40%, while the Vanguard Total International Stock ETF encompasses both developed and emerging markets with around 8,700 stocks, offering broader global investment opportunities.
- Sector Allocation Analysis: The iShares Core MSCI EAFE ETF's top sectors include financials (23%), industrials (19%), and technology (12%), whereas the Vanguard Total International Stock ETF has a higher allocation in technology (21%) alongside financials (22%) and industrials (15%), reflecting a greater emphasis on emerging fields like AI.
- Investment Choice Recommendations: For investors seeking comprehensive international stock coverage in a single fund, the Vanguard Total International Stock ETF is the superior choice, while the iShares Core MSCI EAFE ETF is suitable for those focusing exclusively on developed markets, highlighting the applicability of different investment strategies.
See More
Novartis Gene Therapy Itvisma Approved by European Commission
- Gene Therapy Approval: Novartis' gene therapy Itvisma has been approved by the European Commission for children aged two and older with spinal muscular atrophy (SMA), marking its availability across all 27 EU member states as well as Norway, Iceland, and Liechtenstein.
- Innovative Treatment Option: Itvisma is the first approved gene replacement therapy targeting a broad group of SMA patients, designed to replace the survival motor neuron 1 (SMN1) gene, thereby enhancing Novartis' product offerings in the SMA treatment landscape.
- Market Competitive Edge: Together with the existing Zolgensma therapy, Itvisma provides gene replacement therapy options for SMA patients at various stages, from newborns to adults, significantly strengthening Novartis' competitive position in the European market.
- Clinical Research Backing: The approval follows the pivotal STEER study results, which demonstrated Itvisma's statistically significant improvement on SMA disease progression scales, further solidifying Novartis' leadership in muscle disease therapies.
See More
ADMA Biologics Shows Promising Profitability Outlook
- Profitability Growth: ADMA Biologics reported a net income of $407 million in Q1, reflecting a 22% year-over-year increase, indicating sustained profitability that is expected to enhance the company's competitive edge in the biopharmaceutical market.
- Significant Market Potential: Currently capturing only 4% of its total addressable market, ADMA is positioned for substantial growth, with the market projected to expand at a compound annual growth rate of 10% through 2033, suggesting significant revenue growth opportunities ahead.
- Optimistic Product Outlook: EyePoint Pharmaceuticals is on track to announce results from clinical trials for Duravyu, targeting wet age-related macular degeneration, with a market opportunity exceeding $15 billion, which could significantly elevate the company's market position if approved.
- Investment Risks and Rewards: Viking Therapeutics has an average price target 146% above its current share price, and while it remains unprofitable, its potential in obesity drug development makes it a focal point for investors, despite the inherent investment risks.
See More
